Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials

por Catapano, Alberico L., Lee, L. Veronica, Louie, Michael J., Thompson, Desmond, Bergeron, Jean, Krempf, Michel
Publicado 2017

Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials

por Bays, Harold E., Rosenson, Robert S., Baccara-Dinet, Marie T., Louie, Michael J., Thompson, Desmond, Hovingh, G. Kees
Publicado 2018

Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 OD...

por Bays, Harold E., Leiter, Lawrence A., Colhoun, Helen M., Thompson, Desmond, Bessac, Laurence, Pordy, Robert, Toth, Peter P.
Publicado 2017

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia

por Ginsberg, Henry N., Tuomilehto, Jaakko, Hovingh, G. Kees, Cariou, Bertrand, Santos, Raul D., Brown, Alan S., Sanganalmath, Santosh K., Koren, Andrew, Thompson, Desmond, Raal, Frederick J.
Publicado 2019

Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin

por Müller-Wieland, Dirk, Rader, Daniel J, Moriarty, Patrick M, Bergeron, Jean, Langslet, Gisle, Ray, Kausik K, Manvelian, Garen, Thompson, Desmond, Bujas-Bobanovic, Maja, Roth, Eli M
Publicado 2019